Invesco Dynamic Biotechnology & Genome ETF
Price through Oct 2 · Flows through Oct 1. Figures use the latest available records, not a live quote. Fund details retrieved Oct 2. Holdings snapshot retrieved Oct 2.
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 1M SHOWN · NET −$55M OVER THIS RANGE
Money is leaving — −$55M in net outflows over the past month, about 13.0% of the fund's asset base, while the price has returned +15.7% so far this year. At 0.58% a year it is not the cheapest way in — FDHT has a reported fee of 0.39%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | NTRANATERA | 6.23% | $410.35 | +0.5% | ||
| 2 | ILMNILLUMINA | 6.17% | $273.04 | +2.8% | ||
| 3 | BIIBBIOGEN | 5.19% | $219.88 | -1.3% | ||
| 4 | GILDGILEAD SCIENCES | 5.08% | $144.74 | -1.9% | ||
| 5 | RPRXROYALTY PHARMA | 4.77% | $57.16 | -0.8% | ||
| 6 | VRTXVERTEX PHARMACEUTICALS | 4.80% | $504.73 | -0.4% | ||
| 7 | AMGNAMGEN | 4.84% | $403.04 | -1.0% | ||
| 8 | REGNREGENERON PHARMACEUTICALS | 4.62% | $735.20 | +0.1% | ||
| 9 | MRNAMODERNA | 3.36% | $190.01 | +0.6% | ||
| 10 | NVAXNOVAVAX | 3.17% | $10.46 | -1.3% | ||
| 11 | UTHRUNITED THERAPEUTICS | 2.89% | $541.70 | -5.2% | ||
| 12 | VCYTVERACYTE | 2.89% | $45.81 | +3.7% | ||
| 13 | EXELEXELIXIS | 2.85% | $58.39 | +0.8% | ||
| 14 | QGENQIAGEN NV | 2.77% | $44.75 | +6.4% | ||
| 15 | HALOHALOZYME THERAPEUTICS | 2.80% | $109.86 | +2.7% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.
Sign in to see all 31| 1 week | -2.3% |
| 1 month | -3.7% |
| 3 months | +3.3% |
| 6 months | +20.1% |
| YTD | +15.7% |
| 1 year | +32.0% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | — |
| 1 month | −$55M |
| 3 months | +$116M |
| YTD | +$114M |
| 1 year | +$114M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 6.2% of the book; the top ten carry 48%. Spread across 32+ names, it behaves like roughly 27 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| MRNA MODERNA | $24M | $31M |
| VRTX VERTEX PHARMACEUTICALS | $2M | $3M |
| NTRA NATERA | $1M | $3M |
| AMGN AMGEN | $1M | $2M |
| REGN REGENERON PHARMACEUTICALS | $729,961 | $1M |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat PBE on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| IVV iShares Core S&P 500 ETF | 0.03% | $882.6B | +$4.6B | -55bp on fee · 2084× the assets · +$4.6B in over the month | Head-to-head |
| SPDW State Street SPDR Portfolio Developed World ex-US ETF | 0.03% | $41.5B | +$286M | -55bp on fee · 98× the assets · +$286M in over the month | Head-to-head |
| BBUS JPMorgan BetaBuilders U.S. Equity ETF | 0.02% | $9.4B | +$187M | -56bp on fee · 22× the assets · +$187M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.2B | +$199M | -55bp on fee · 43× the assets · +$199M in over the month | Head-to-head |
| SPYG State Street SPDR Portfolio S&P 500 Growth ETF | 0.04% | $56.2B | +$717M | -54bp on fee · 133× the assets · +$717M in over the month | Head-to-head |